198 related articles for article (PubMed ID: 30103404)
1. Pseudopterosin Inhibits Proliferation and 3D Invasion in Triple-Negative Breast Cancer by Agonizing Glucocorticoid Receptor Alpha.
Sperlich J; Teusch N
Molecules; 2018 Aug; 23(8):. PubMed ID: 30103404
[TBL] [Abstract][Full Text] [Related]
2. The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-κB Signaling.
Sperlich J; Kerr R; Teusch N
Mar Drugs; 2017 Aug; 15(9):. PubMed ID: 28832545
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
4. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
5. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
[TBL] [Abstract][Full Text] [Related]
7. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Sambi M; Samuel V; Qorri B; Haq S; Burov SV; Markvicheva E; Harless W; Szewczuk MR
Drug Des Devel Ther; 2020; 14():1995-2019. PubMed ID: 32546966
[TBL] [Abstract][Full Text] [Related]
8. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
9. Lactate dehydrogenase downregulation mediates the inhibitory effect of diallyl trisulfide on proliferation, metastasis, and invasion in triple-negative breast cancer.
Cheng SY; Yang YC; Ting KL; Wen SY; Viswanadha VP; Huang CY; Kuo WW
Environ Toxicol; 2017 Apr; 32(4):1390-1398. PubMed ID: 27566995
[TBL] [Abstract][Full Text] [Related]
10. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
12. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
14. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
[TBL] [Abstract][Full Text] [Related]
15. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
16. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
[TBL] [Abstract][Full Text] [Related]
17. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
18. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Hsiao YC; Yeh MH; Chen YJ; Liu JF; Tang CH; Huang WC
Oncotarget; 2015 Nov; 6(35):37965-78. PubMed ID: 26513016
[TBL] [Abstract][Full Text] [Related]
20. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
